Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) – Pipeline Review, H2 2016’, provides in depth analysis on Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1)

The report reviews Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Bristol-Myers Squibb Company

Daiichi Sankyo Company Ltd

Galapagos NV

Merrimack Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC

2.7.10.1) Overview 6

Therapeutics Development 7

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC

2.7.10.1) - Products under Development by Stage of Development 7

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC

2.7.10.1) - Products under Development by Therapy Area 8

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC

2.7.10.1) - Products under Development by Indication 9

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC

2.7.10.1) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC

2.7.10.1) - Products under Development by Companies 12

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC

2.7.10.1) - Products under Development by Universities/Institutes 14

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC

2.7.10.1) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC

2.7.10.1) - Companies Involved in Therapeutics Development 23

Bristol-Myers Squibb Company 23

Daiichi Sankyo Company Ltd 24

Galapagos NV 25

Merrimack Pharmaceuticals Inc 26

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC

2.7.10.1) - Drug Profiles 27

Antisense RNAi Oligonucleotide to Inhibit EPHA2 for Solid Tumor and Ovarian Cancer - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

dasatinib - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

DS-8895 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

GLPG-1790 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

MM-310 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Monoclonal Antibodies to Activate EPHA2 for Oncology - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC

2.7.10.1) - Dormant Projects 35

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC

2.7.10.1) - Discontinued Products 36

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC

2.7.10.1) - Featured News & Press Releases 37

Nov 17, 2016: NICE ‘yes’ for chronic myeloid leukaemia pill 37

Nov 17, 2016: NICE approves three quarters of CDF group 1 drugs for routine use 38

Nov 03, 2016: Bristol-Myers Squibb to Present New Data On Sprycel at the 58th Annual Meeting & Exposition of the American Society of Hematology 38

Sep 12, 2016: Scottish NHS patients granted access to pivotal treatment for chronic myeloid leukaemia 40

Jun 29, 2016: Leukaemia drug shows potential for rarer type of ovarian cancer 41

Jun 09, 2016: Bristol-Myers Squibb to Present Data on Sprycel (dasatinib) at the 21st Congress of the European Hematology Association 42

Apr 21, 2016: Merrimack Unveils its Latest Antibody Directed Nanotherapeutic, MM-310, at the 2016 AACR Annual Meeting 42

Mar 16, 2016: Merrimack to Present on MM-310 at the 2016 American Association for Cancer Research Annual Meeting 43

Aug 13, 2015: FDA Approves U.S. Product Labeling Update for Sprycel (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase 44

Jul 06, 2015: Delhi High Court Upholds BMS’ Patent For Dasatinib 45

Jun 29, 2015: Mayo Clinic study suggests which glioblastoma patients may benefit from drug treatment 45

Nov 07, 2014: Bristol-Myers Squibb Announces Oral Presentations of Sprycel at 56th Annual American Society for Hematology (ASH) Meeting 46

Oct 19, 2014: DIPP Seeks Information On Dasatinib For Issuance Of Compulsory Licences 46

May 07, 2014: India Seeks Waiver Of Bristol-Myers Squibb's Patent Rights For Dasatinib 47

Mar 18, 2014: Galapagos to present favorable pre-clinical data on GLPG1790, a selective ephrin receptor kinase inhibitor, at AACR in San Diego 47

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by Bristol-Myers Squibb Company, H2 2016 23

Pipeline by Daiichi Sankyo Company Ltd, H2 2016 24

Pipeline by Galapagos NV, H2 2016 25

Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 26

Dormant Projects, H2 2016 35

Discontinued Products, H2 2016 36

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Mechanism of Actions, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 21

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports